PTCT news

PT Therapeutics, Inc. announced its Board of Directors authorized a $500 million share repurchase program to invest in the company. This news might appeal to value investors viewing the undervaluation as an opportunity to acquire shares.

PTC Therapeutics reported record third-quarter revenue, significantly raising full-year guidance. The company secured regulatory approval for its Fabry gene therapy, indicating ongoing pipeline diversification and success of the Sephience launch.

PTC Therapeutics reported Q2 2026 revenue of $361 million, raised full-year product revenue guidance, and announced strong Sephience revenue, a $50 million Novartis milestone, and new pipeline developments.

PTC Therapeutics announced pricing of $500 million in 0% convertible senior notes due 2031, with net proceeds to refinance $222 million of 2026 convertible notes. The offering includes a 40% conversion premium and represents a refinancing strategy to extend debt maturity while maintaining financial …

PTC Therapeutics has engaged former Board member Alethia Young as an independent consultant effective June 8, 2026, following her resignation from the board. The agreement outlines advisory services to management and the board with standard confidentiality and intellectual property protections for a…